10-Q · May 15, 2026
GT Biopharma's Q1 2026 report shows no revenue, an increased net loss of $2.83 million, and significant changes in operating expenses driven by higher selling, general, and administrative costs. The company remains in…
Earnings analysis · 10-Q
GTBP earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The provided 10-Q extract does not include the income statement, balance sheet, cash flow statement, or MD&A, so revenue, margins, EPS, liquidity, working-capital trends, and free cash flow cannot be assessed. The most…
Read full summary
The provided 10-Q extract does not include the income statement, balance sheet, cash flow statement, or MD&A, so revenue, margins, EPS, liquidity, working-capital trends, and free cash flow cannot be assessed. The most material disclosed issue is that disclosure controls remained ineffective as of June 30, 2026 due to an unremediated material weakness. Legal exposure remains relevant, including three convertible-note claims seeking damages in excess of $500,000 each and a pending appeal with a September 25, 2026 perfection deadline.
What stood out
-
Ohri Arbitration Resolved
The company states that the arbitration involving former CFO Manu Ohri was resolved amicably on March 31, 2026, without further litigation.
-
Accounting Remediation Implemented
Management implemented additional controls subsequent to September 30, 2025 requiring a qualified accounting consultant to review transactions involving stock purchase rights, derivatives, or other complex financial arrangements.
-
Advisory Warrant Issued
During the second quarter of 2026, the company issued PDPC Advisors a pre-funded warrant to purchase 400,000 common shares.
-
Preferred Dividend Paid in Shares
On June 24, 2026, the company issued 175,015 common shares as a dividend to Series L Preferred Stock holders, representing 12% of the outstanding stated value of the Series L Preferred Stock for the three months ended June 30, 2026.
What to watch
-
Unremediated Control Weakness
Disclosure controls and procedures were not effective as of June 30, 2026 because the material weakness identified for the year ended December 31, 2025 has not been fully remediated. The weakness relates to accounting for complex transactions, specifically ASC 480 and certain Greenshoe Rights.
-
Convertible Note Litigation
The company disclosed ongoing litigation from three plaintiffs involving convertible notes with stated principal amounts of $100,000 each, although the Silberfein complaint alleges $150,000; each plaintiff is seeking damages in excess of $500,000. The company has reached a settlement in principle but is still finalizing the agreements.
-
Pending Legal Appeal
Z-One, LLC filed a notice of appeal on March 26, 2026 after its claims were dismissed with prejudice on February 27, 2026; the appeal must be perfected by September 25, 2026.
-
No Formal Risk-Factor Update
The filing states there were no material changes from the risk factors in the December 31, 2025 Form 10-K. Accordingly, no new formal risk-factor changes were identified in this 10-Q.
Management's outlook
The provided 10-Q text contains no quantitative revenue or EPS outlook. Outlook was not provided in the extracted filing text.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.